1. Home
  2. LADR vs MESO Comparison

LADR vs MESO Comparison

Compare LADR & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LADR
  • MESO
  • Stock Information
  • Founded
  • LADR 2008
  • MESO 2004
  • Country
  • LADR United States
  • MESO Australia
  • Employees
  • LADR N/A
  • MESO N/A
  • Industry
  • LADR Real Estate Investment Trusts
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LADR Real Estate
  • MESO Health Care
  • Exchange
  • LADR Nasdaq
  • MESO Nasdaq
  • Market Cap
  • LADR 1.5B
  • MESO 1.3B
  • IPO Year
  • LADR 2014
  • MESO N/A
  • Fundamental
  • Price
  • LADR $11.13
  • MESO $11.06
  • Analyst Decision
  • LADR Strong Buy
  • MESO Buy
  • Analyst Count
  • LADR 5
  • MESO 4
  • Target Price
  • LADR $13.15
  • MESO $18.00
  • AVG Volume (30 Days)
  • LADR 762.7K
  • MESO 205.5K
  • Earning Date
  • LADR 07-24-2025
  • MESO 08-28-2025
  • Dividend Yield
  • LADR 8.27%
  • MESO N/A
  • EPS Growth
  • LADR 7.86
  • MESO N/A
  • EPS
  • LADR 0.82
  • MESO N/A
  • Revenue
  • LADR $259,161,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • LADR N/A
  • MESO $178.09
  • Revenue Next Year
  • LADR $16.49
  • MESO $305.06
  • P/E Ratio
  • LADR $13.58
  • MESO N/A
  • Revenue Growth
  • LADR 1.39
  • MESO N/A
  • 52 Week Low
  • LADR $9.68
  • MESO $5.78
  • 52 Week High
  • LADR $12.48
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • LADR 63.49
  • MESO 50.02
  • Support Level
  • LADR $10.90
  • MESO $10.32
  • Resistance Level
  • LADR $11.23
  • MESO $10.86
  • Average True Range (ATR)
  • LADR 0.17
  • MESO 0.35
  • MACD
  • LADR 0.03
  • MESO 0.00
  • Stochastic Oscillator
  • LADR 85.42
  • MESO 45.04

About LADR Ladder Capital Corp

Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: